Used in cancer immunotherapy research to target the B7-H6/NCR3LG1 immune checkpoint pathway. This antibody binds specifically to B7-H6, a protein often overexpressed on tumor cells, helping to block immune evasion and enhance natural killer (NK) cell activation against cancers. It serves as a reference tool for developing therapeutic antibodies and diagnostic assays. Also utilized in mechanistic studies to understand tumor-immune interactions and in the design of antibody-drug conjugates or bispecific antibodies for targeted cancer treatment.